Updated:
Harrow Health
Harrow Health is a Nashville-based ophthalmic pharmaceutical company led by CEO Mark Baum. Focused on acquiring and commercializing eye-care drugs.
Harrow Health
Harrow Health was founded in 2010 and is led by CEO Mark Baum. The company positions itself as a specialty pharmaceutical firm with a focus on ophthalmic therapeutics. Harrow's strategy involves acquiring late-stage or approved compounds and leveraging its commercial infrastructure to maximize sales. The company's portfolio includes FDA-approved medications for conditions such as dry eye, glaucoma, and inflammation. Harrow employs a direct sales force that calls on ophthalmologists and optometrists in the United States. The firm operates from Nashville and has a team of approximately 140 employees, as reported in its 2023 annual filing. Harrow Health is publicly traded on the NASDAQ under the ticker HROW. In 2023, the company reported revenue of $129 million (per SEC filing). A structural differentiator is Harrow's focus on the ophthalmic market, which is a niche within specialty pharmaceuticals. The company avoids broad-based drug development and instead targets a single therapeutic category, allowing for focused commercial investment.
General information
Firm type
Public Company
Year founded
2010
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Nashville
Corporate office
Nashville, TN, United States
Principals
Mark L. Baum
CEO
Andrew R. Boll
CFO
Sector focus
Frequently asked questions
Who runs investment decisions at Harrow Health?
CEO Mark Baum leads executive decisions, including acquisition strategy for Harrow Health. The board of directors provides oversight. The company's capital allocation is disclosed in its quarterly earnings reports and SEC filings.
Does Harrow Health own pharmaceutical products or is it a development-stage company?
Harrow owns a portfolio of FDA-approved ophthalmic products and commercializes them through a direct sales force. It has multiple approved drugs on the market, including products for dry eye and glaucoma treatment.
How is Harrow Health structured legally?
Harrow Health is a publicly traded corporation listed on NASDAQ under the ticker HROW. It files regular financial reports with the SEC, including 10-K and 10-Q documents.
Where does Harrow Health generate revenue?
The company generates revenue primarily from product sales of its ophthalmic drugs. Its sales force targets eye care professionals in the US. Revenue is reported in its annual filings.
What investment stages does Harrow Health typically target?
Harrow Health focuses on acquiring late-stage or already-approved ophthalmic drugs. It does not typically engage in early-stage drug discovery or preclinical development.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: